Norspan (Buprenorphine)

Buprenorphine acts as a high‑affinity partial agonist at the μ‑opioid receptor, producing analgesia while limiting the maximal effect on respiratory drive. It also antagonizes κ‑opioid receptors, which can reduce dysphoric effects. When delivered via a transdermal patch, the drug is absorbed through the skin, maintaining relatively constant systemic concentrations.

The specific dose and patch strength are determined by the prescribing clinician based on the individual’s pain severity, prior opioid exposure, and clinical response. Norspan is available in different release rates, and the prescriber selects the appropriate strength and replacement interval for each patient.

Limited clinical data are available on the use of buprenorphine patches during pregnancy or lactation. Because opioids can affect fetal development and may be excreted in breast milk, the potential benefits must be weighed against possible risks. Treatment decisions should be made by a qualified healthcare professional in consultation with the patient.

To request Norspan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to buprenorphine patches is the fentanyl transdermal system. Both provide continuous opioid delivery, but buprenorphine has a ceiling effect for respiratory depression and a lower risk of severe respiratory compromise. Fentanyl is a full μ‑opioid agonist and may produce stronger analgesia but carries a higher potential for respiratory depression and overdose.

Norspan patches should be stored at room temperature, preferably below 25 °C, in their original protective pouch. Keep them away from direct sunlight, moisture and heat sources. Do not expose the patches to temperatures above the recommended range, as this may affect drug stability and release characteristics.

The patch is applied to clean, dry, hair‑free skin on the upper torso, upper arm, or back. Press the patch firmly for about 30 seconds to ensure good contact. The patch remains in place for the prescribed duration (usually 7 days) and is then removed and replaced with a new one at a different site to avoid skin irritation.

The most critical risks include respiratory depression, especially in opioid‑naïve patients or when combined with other depressants; severe hypotension; allergic skin reactions such as Stevens‑Johnson syndrome; and adrenal insufficiency with prolonged use. Patients should be monitored closely for signs of breathing difficulty, low blood pressure, rash, or unusual fatigue.

Norspan is contraindicated in individuals with known hypersensitivity to buprenorphine, the patch adhesive, or any excipients. It should also be avoided in patients with severe respiratory insufficiency, acute asthma attacks, or those taking monoamine oxidase inhibitors within 14 days. Caution is advised in the elderly, patients with hepatic impairment, and those on concurrent CNS depressants.